| Similar Articles |
|---|
 |
The Motley Fool
December 11, 2006
Matthew Crews |
Rite Aid: Comps Mean Competition The pharmacy chain reported positive same-store results for November. Investors, take note.   |
The Motley Fool
August 19, 2011
Ilan Moscovitz |
Rite Aid Is Cheaper Than You Think Rite Aid tends to generate much more free cash flow than net income, suggesting that -- while things may not exactly be going swimmingly -- the company's stock might be a bit cheaper than many investors realize. |
The Motley Fool
July 6, 2004
Alyce Lomax |
Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them. |
The Motley Fool
September 29, 2011
Dan Caplinger |
Has Rite Aid Become the Perfect Stock? The company needs to turn itself around first before anyone will seriously expect superior results from Rite Aid. |
The Motley Fool
September 29, 2011
Navjot Kaur |
Should You Write Off Rite Aid? Rite Aid posts a relatively better quarter as wellness rewards the company. |
The Motley Fool
September 24, 2004
Seth Jayson |
Kick This Drug Habit Rite Aid offers slow sales and minuscule shareholder rewards. |
The Motley Fool
January 5, 2007
Matthew Crews |
Rite Aid's Baby Steps If Rite Aid does manage 5% operating margins, this pharmacy chain's shares will get the love they deserve. |
The Motley Fool
June 27, 2011
Shubh Datta |
All Is Not Yet Right at Rite Aid Drug retailer Rite Aid posts losses in its first fiscal quarter and sees further losses ahead. |
The Motley Fool
September 22, 2010
Rich Smith |
Foolish Forecast: A Prescription for Rite Aid Investors Here's what you need to know before earnings come out tomorrow. |
The Motley Fool
June 21, 2006
Rich Smith |
Foolish Forecast: Rite Aid Revival? Will tomorrow's earnings news make it three bad quarters in a row for the retail pharmacy? Investors, take note. |
The Motley Fool
September 25, 2009
Chris Jones |
The First Symptom of Health-Care Troubles? Rite Aid's problems imply bad news for consumers and the health-care system. |
The Motley Fool
April 11, 2008
Ryan Fuhrmann |
Rite Aid Hasn't Fully Recovered Rite Aid needs to be nursed back to health after its acquisition of Brooks Eckerd. |
The Motley Fool
June 24, 2005
Stephen D. Simpson |
Is Rite Aid a Real Value Stock? Reality hasn't caught up with the company's turnaround prospects. Rite Aid must deal with a lot of debt and preferred equity if and when it recovers. |
The Motley Fool
June 29, 2007
Ryan Fuhrmann |
Rite Aid's Recent Remedy Will increased market clout lead the drugstore operator to new highs? Investors, take note. |
The Motley Fool
October 4, 2005
Seth Jayson |
Same Old Same-Store Story Reports from Walgreen and Rite Aid confirm the obvious. Investors will nearly always do better buying the best company in any given space. |
The Motley Fool
June 25, 2004
Steven Mallas |
Rite Aid in the Shadows The first quarter for Rite Aid, the pharmaceutical retailer, shows a profit, but is it time to add this stock to your portfolio? |
The Motley Fool
March 8, 2005
Seth Jayson |
Rite Aid Wretched? Value investors may be interested in Rite Aid. |
The Motley Fool
January 3, 2012
Shubh Datta |
Bright Spots for Rite Aid Better same-store sales help Rite Aid trim losses. |
The Motley Fool
January 4, 2005
Seth Jayson |
Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship. |
The Motley Fool
September 27, 2007
Ryan Fuhrmann |
Rite Aid Looks a Little Peaked Bigger doesn't necessarily mean better for the drugstore retailer; it has quite a bit of work to do to convince investors it can successfully manage the empire that it has acquired. |
The Motley Fool
September 26, 2007
Ryan Fuhrmann |
Foolish Forecast: Does Rite Aid Have the Right Rx? The retail pharmacy is set to release it second-quarter financial results. Investors, here is what you can expect to see. |
The Motley Fool
January 4, 2008
Timothy M. Otte |
Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December. |
The Motley Fool
October 21, 2010
Anand Chokkavelu |
9 Basic Stocks Near 52-Week Lows Here are the largest food and staples stocks by market cap that are hugging 52-week lows: Wal-Mart... CVS... Costco... SYSCO... Kroger... Companhia Brasileira... Safeway... Delhaize... Rite Aid... |
The Motley Fool
June 11, 2007
Mike Cianciolo |
Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note. |
The Motley Fool
September 22, 2006
Ryan Fuhrmann |
More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note. |
The Motley Fool
September 22, 2005
Stephen D. Simpson |
Rite Aid Not Right Yet The bleeding seems to have stopped at this pharmacy, but recovery could be a long and slow road. Intrepid, not to mention patient, investors may see potential here, but there are far better turnaround ideas to be had. |
The Motley Fool
April 13, 2007
Ryan Fuhrmann |
Rite Aid's Right-Size Ambitions If the retail pharmacy chain can improve its net margins, reduce debt, and smoothly integrate its latest acquisition, the stock's upside would be substantial. |
Fast Company
Neal Ungerleider |
Rite Aid Will Now Support Apple Pay And Google Wallet "By accepting mobile payments, we're able to offer Rite Aid customers an easy and convenient checkout process, which we know is important to them," Rite Aid CEO Ken Martindale said in a statement |
The Motley Fool
December 19, 2011
Seth Jayson |
Golf Clap for Rite Aid Rite Aid reported revenue of $6.3 billion. The five analysts polled by S&P Capital IQ looked for revenue of $6.3 billion. |
The Motley Fool
June 25, 2007
Ryan Fuhrmann |
Foolish Forecast: Rite Aid Aims for Healthy Growth The drugstore operator is set to report its first-quarter earnings. Investors, here is what you can expect to see. |
The Motley Fool
January 3, 2005
Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground. |
The Motley Fool
June 22, 2006
Stephen D. Simpson |
Rite Aid: Not Quite Rad, but Not All Bad Better results are possible, but there might be better ideas for investors. |
The Motley Fool
September 7, 2004
Seth Jayson |
Rejecting Rite Aid Shares of the drugstore chain droped 13%, and may prove to be a bargain if this is indeed a temporary slowdown and management can deliver more robust growth. |
The Motley Fool
April 20, 2011
Alyce Lomax |
Watchful Eyes on Wasteful Practices CEO pay disparities continue to fly in the face of fiscal prudence. |
The Motley Fool
April 12, 2007
Ryan Fuhrmann |
Rite Aid Ekes Out a Gain: Fool by Numbers The drugstore retailer released fourth-quarter and year-end 2007 results: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
August 13, 2010
Jim Mueller |
How Well Do You Use Cash, Rite Aid? Between retail and pharmacy, Rite Aid isn't doing too well, at least when compared to purer plays on either sector. |
The Motley Fool
April 8, 2004
Seth Jayson |
Rite Aid Wrings Out Profits Net store closings and comps increases bring black ink to the pharmacy's bottom line. |
The Motley Fool
March 24, 2004
Dave Marino-Nachison |
Eking Out an Eckerd Deal Investors are still waiting for a new leader to be crowned in the U.S. drugstore business. |
The Motley Fool
September 14, 2006
Ryan Fuhrmann |
Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector. |
The Motley Fool
April 6, 2006
Stephen D. Simpson |
Rite Aid Regains Respectability The pharmacy's slow, steady turnaround may not be enough. There have been so many dilutive financing events that it's no longer clear whether common equity shareholders will gain enough bang to compensate for the risk. |
The Motley Fool
March 9, 2004
Alyce Lomax |
February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers. |
The Motley Fool
February 4, 2005
Steven Mallas |
Walgreen's Wonderful Comps This drugstore chain doesn't need any medical attention. January comps prove it. |
The Motley Fool
December 6, 2007
Selena Maranjian |
Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall. |
The Motley Fool
April 5, 2006
Rich Smith |
Foolish Forecast: Rite Aid Writes a Script Although the retail pharmacy isn't setting the world on fire with its turnaround, its gross margins have inched up slightly over the last 18 months. Investors, take note. |
The Motley Fool
September 27, 2007
Anders Bylund |
Rite Aid's Strong Prescription: Fool by Numbers The fast facts on convenience store and pharmacy operator Rite Aid's second-quarter 2008 reports. Despite peaked sales, the company's recent remedy of adding new brand-name stores to its portfolio didn't seem to trickle to the bottom line. |
The Motley Fool
July 6, 2007
Timothy M. Otte |
Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's... |
The Motley Fool
July 6, 2004
Steven Mallas |
Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%. |
The Motley Fool
June 21, 2004
Seth Jayson |
Walgreen's Fine Follow-Up It's another solid quarter for America's soon-to-be No. 2 drugstore. |
The Motley Fool
March 24, 2011
Rick Aristotle Munarriz |
It's a Dot-Com Drug Deal Gone Bad The drugstore giant acquires the drugstore.com pipsqueak. |
The Motley Fool
April 4, 2007
Timothy M. Otte |
Walgreen's Comp Machine The drugstore operator steams through March with 8% comparable sales growth. The stock trades at a P/E of 24 times trailing-12-month earnings, about one-third higher than the average of all S&P 500 companies. |
